Ann: DISCO topline results, page-2

Strong Clinical Efficacy Data (vs. SOC)

• 64Cu-SARTATE showed nearly double the lesion detection vs. 68Ga-DOTATATE.

• This is clinically meaningful and suggests a best-in-class diagnostic in neuroendocrine tumours (NETs).

De-risked Path to Phase III

• The company announced it will initiate a registrational Phase III trial under FDA guidance.

• A transition to Phase III with compelling Phase II data is a major milestone in biotech investing.

Clear Commercial Potential

• NET diagnostic market in the U.S. estimated at 100,000 scans/year, growing to 120,000 by 2029.

• Clarity estimates addressable market could rival that of prostate cancer imaging, a multibillion-dollar sector.

Favourable Safety Profile

• No serious adverse events observed; trial drug was well tolerated—critical for both regulatory and market acceptance.

Investor Sentiment Catalyst

• Results demonstrate validation of Clarity’s Targeted Copper Theranostics platform, lifting confidence in broader pipeline.

• Could attract institutional interest or analyst upgrades.